@article{ref1,
title="Notes from the field: Pediatric emergency department visits for buprenorphine/naloxone ingestion - United States, 2008-2015",
journal="MMWR: Morbidity and mortality weekly report",
year="2016",
author="Budnitz, Daniel S. and Lovegrove, Maribeth C. and Sapiano, Mathew R. P. and Mathew, Justin and Kegler, Scott R. and Geller, Andrew I. and Hampp, Christian",
volume="65",
number="41",
pages="1148-1149",
abstract="Expanding access to office-based medication-assisted treatment with buprenorphine/naloxone for opioid dependence is a key part of the national strategy to address the opioid abuse epidemic (1). However, as buprenorphine/naloxone prescribing increased, emergency department (ED) visits and hospitalizations for unsupervised ingestions by young children began to increase, with buprenorphine/naloxone ingestions becoming the most common cause of hospitalization for medication ingestions by young children during 2010-2011 (2). Buprenorphine ingestions might be asymptomatic or can cause drowsiness, vomiting, or respiratory depression, which if untreated can result in death (3). Buprenorphine/naloxone was available only as tablets in multidose child-resistant bottles (Suboxone) until late 2010, when film strips packaged in unit-dose, child-resistant pouches were introduced. In 2013, tablets became available in unit-dose packaging (Zubsolv). Because unit-dose, child-resistant packaging encloses each dose until opened, it might limit unintended ingestions by young children compared with traditional child-resistant bottles that must be resecured after every use (4). This study compared ED visits for pediatric buprenorphine/naloxone ingestions before and after these product packaging/formulation changes.<p /> <p>Language: en</p>",
language="en",
issn="0149-2195",
doi="10.15585/mmwr.mm6541a5",
url="http://dx.doi.org/10.15585/mmwr.mm6541a5"
}